Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance

Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance

<strong>Aims<br></strong> Robust diabetes risk estimates in Asian patients with impaired glucose tolerance (IGT) and coronary heart disease (CHD) are lacking. We developed a Chinese type 2 diabetes risk calculator using Acarbose Cardiovascular Evaluation (ACE) trial data. <br>...

Bibliografske podrobnosti
Main Authors:	Xu, S, Scott, CAB, Coleman, RL, Tuomilehto, J, Holman, RR
Format:	Journal article
Jezik:	English
Izdano:	Wiley 2021

Podobne knjige/članki

Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
od: Xu, S, et al.
Izdano: (2019)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
od: Wamil, M, et al.
Izdano: (2020)

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): a longitudinal analysis of a randomized, double-blind, placebo-controlled trial
od: Leal, J, et al.
Izdano: (2022)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
od: Califf, R, et al.
Izdano: (2003)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
od: Currie, G, et al.
Izdano: (2017)

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial
od: Liam Mc Morrow, et al.
Izdano: (2024-02-01)

Impaired glucose tolerance: who and how treats it?
od: M. N. Mamedov
Izdano: (2005-12-01)

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
od: Holman, R, et al.
Izdano: (2017)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
od: Yates, T, et al.
Izdano: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
od: Yates, T, et al.
Izdano: (2014)

Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89
od: Wamil, M, et al.
Izdano: (2021)

Perceived Symptoms in People Living with Impaired Glucose Tolerance
od: Susanne Andersson, et al.
Izdano: (2011-01-01)

Prevalence of Impaired Fasting Glucose and Impaired Glucose Tolerance in Non-Diabetic Patients with Coronary Artery Disease
od: Nihar Ranjan Mohanty, et al.
Izdano: (2022-06-01)

Increased risk of incident heart failure and all-cause mortality in insulin-resistant people with type 2 diabetes in the United Kingdom Prospective Diabetes Study (UKPDS)
od: Wamil, M, et al.
Izdano: (2020)

Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.
od: Farrer, M, et al.
Izdano: (1993)

Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance
od: Fang Zhang, Xialian Tang, Hongyi Cao, Qingguo Lü, Nali Li, Yupu Liu, Xiangxun Zhang, Yuwei Zhang, Mingming Cao, Jun Wan, Zhenmei An, Nanwei Tong
Izdano: (2012-01-01)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
od: Preiss, D, et al.
Izdano: (2013)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
od: Califf, R, et al.
Izdano: (2008)

Expert Workshop on Impaired Glucose Tolerance Held in London, UK - 29 March 1995 - Introduction
od: Holman, R
Izdano: (1996)

Effect of Apple Consumption on Postprandial Blood Glucose Levels in Normal Glucose Tolerance People versus Those with Impaired Glucose Tolerance
od: Yutaka Inoue, et al.
Izdano: (2022-06-01)

'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
od: Page, R, et al.
Izdano: (1993)

Variations in the ghrelin receptor gene associate with obesity and glucose metabolism in individuals with impaired glucose tolerance.
od: Ursula Mager, et al.
Izdano: (2008-08-01)

Relationship between BMI and risk of impaired glucose tolerance and impaired fasting glucose in Chinese adults: a prospective study
od: Xin Zhang, et al.
Izdano: (2023-01-01)

Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes.
od: Anke Tönjes, et al.
Izdano: (2010-01-01)

Associations of green tea and rock tea consumption with risk of impaired fasting glucose and impaired glucose tolerance in Chinese men and women.
od: Huibin Huang, et al.
Izdano: (2013-01-01)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
od: Gerstein, H, et al.
Izdano: (2006)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
od: Preiss, D, et al.
Izdano: (2012)

Resting heart rate and impaired glucose regulation in middle-aged and elderly Chinese people: a cross-sectional analysis
od: Zhen Yang, et al.
Izdano: (2017-09-01)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
od: Dos Santos, M, et al.
Izdano: (2017)

Impaired glucose tolerance in sleep disorders.
od: Marietta Keckeis, et al.
Izdano: (2010-03-01)

Framingham risk equations underestimate coronary heart disease risk in diabetes.
od: Stevens, R, et al.
Izdano: (2005)

Metabolic disorders in patients with impaired glucose tolerance, with or without underlying ischaemic heart disease
od: Brkić Milena, et al.
Izdano: (2022-01-01)

Evidence From a Systematic Review and Meta-Analysis: Classical Impaired Glucose Tolerance Should Be Divided Into Subgroups of Isolated Impaired Glucose Tolerance and Impaired Glucose Tolerance Combined With Impaired Fasting Glucose, According to the Risk of Progression to Diabetes
od: Yupu Liu, et al.
Izdano: (2022-02-01)

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
od: Mostafa, SA, et al.
Izdano: (2017)

Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
od: Mc Morrow, L, et al.
Izdano: (2018)

Impaired Sensitivity to Thyroid Hormones Is Associated With Elevated Blood Glucose in Coronary Heart Disease
od: Lu Yu, et al.
Izdano: (2022-06-01)

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
od: Marilia Harumi Higuchi dos Santos, et al.
Izdano: (2017-01-01)

List of people who have paid
od: Cork County Association, CCA

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
od: Latini, R, et al.
Izdano: (2013)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
od: Sharma, A, et al.
Izdano: (2016)